Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype

NCT06506227 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2024-07-17

No results posted yet for this study

Summary

Mining AIS biomarkers, elucidating the new mechanism of AIS pathogenicity, constructing risk prediction models, optimizing AIS precise diagnosis and treatment techniques, formulating precise diagnosis and treatment protocols and technical specifications for AIS combined with Chinese and Western medicine with independent intellectual property rights, and realizing the full coverage of Zhejiang Province by the end of 2026, so as to form the "Zhejiang experience" of AIS diagnosis and treatment.

Conditions

  • Adolescent Idiopathic Scoliosis

Interventions

BEHAVIORAL

Low risk experimental group

Guiding + Manipulation + Traditional Chinese Medicine

BEHAVIORAL

Medium risk experimental group

Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces

GENETIC

High risk experimental group

Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation

BEHAVIORAL

Control group COBB 10-20°

Specific Exercise Therapy

BEHAVIORAL

Control group COBB 20-45°

Orthopedic Braces + Specific Exercise Therapy

BEHAVIORAL

Control group COBB >45°

Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery

OTHER

Experimental group (AIS group)

Molecular marker exploration and validation

OTHER

Control group (healthy control)

Molecular marker exploration and validation

OTHER

Controlled follow-up before and after AIS

Construction and validation of AIS risk prediction model completed

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhejiang Chinese Medical University

    lead OTHER

Principal Investigators

  • Jiang Zhong, bachelor · The First Affiliated Hospital of Zhejiang Chinese Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06506227 on ClinicalTrials.gov